Q1 FY27 results reported
As filed · Outcome of Board Meeting
What happened
FactOutcome of Board Meeting. Unaudited Standalone Financial Results for the quarter ended 30th June, 2026. Unaudited Consolidated Financial Results for the quarter ended 30th June,.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
WithdrawnWe have acquired a 50 acre freehold land parcel at Dahej and already applied for environmental clearance for the upcoming Dahej site with comprehensive long term view-point.
SCIL has plans to strategically invest in augmenting its R&D facilities, with a key focus on leveraging SCC Japan’s cutting-edge chemistries to create novel processes and combinations.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- The commercialization of Excalia Max and Lentigo, both high potential patented molecules from SCC, is expected (management committed by FY26)
- Building on the momentum of FY '25, we enter FY '26 with renewed strategic intent and operational confidence. (management committed by FY26)
Evidence
- Outcome of Board Meeting(opens the original filing in a new tab)
- Earlier statement · FY23
- Latest statement · FY23
- Earlier statement · Q2 FY22
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%